Ascendis Pharma to Initiate TransCon™ PTH U.S. Expanded Access Program for Adult Patients with Hypoparathyroidism
05 déc. 2022 08h00 HE
|
Ascendis Pharma
- The program will allow physicians to request access to TransCon PTH, the company’s investigational parathyroid hormone replacement therapy, for eligible patients in the United States - TransCon...
Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference
22 nov. 2022 08h30 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to participate in the 5th Annual Evercore ISI HealthCONx...
Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ PTH in Adult Patients with Hypoparathyroidism
14 nov. 2022 07h00 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines...
Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years
13 nov. 2022 18h15 HE
|
Ascendis Pharma
- Data demonstrated that once-weekly TransCon CNP has the potential to meet patient and caregiver needs for a safe, effective, tolerable and convenient treatment - The primary endpoint,...
Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022
11 nov. 2022 12h10 HE
|
Ascendis Pharma
- Early signs of clinical activity were observed in patients receiving TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab; abscopal effect observed with monotherapy - With a...
Ascendis Pharma Reports Third Quarter 2022 Financial Results
02 nov. 2022 16h01 HE
|
Ascendis Pharma
- SKYTROFA® U.S. revenue more than doubled quarter-to-quarter again, reaching €12.3 million in the third quarter - FDA accepted for Priority Review TransCon™ PTH NDA in adult patients with...
FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism
31 oct. 2022 08h00 HE
|
Ascendis Pharma
- PDUFA target action date is April 30, 2023 - MAA submission to EMA on track for this quarter COPENHAGEN, Denmark, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today...
Ascendis Pharma A/S Announces Third Quarter 2022 Financial Results and Business Update Conference Call on November 2
26 oct. 2022 08h00 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, November 2,...
Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for transcendIT-101, a Phase 1/2 Clinical Trial of TransCon™ TLR7/8 Agonist in Solid Tumors
03 oct. 2022 08h00 HE
|
Ascendis Pharma
- TransCon TLR7/8 Agonist continued to be well-tolerated and demonstrated early signs of clinical activity as monotherapy or in combination with pembrolizumab - Abstract for dose-escalation topline...
New Long-Term Data in Adult Patients with Hypoparathyroidism Treated with Ascendis Pharma’s TransCon™ PTH through Week 110 in the PaTH Forward Trial Presented at ASBMR 2022
12 sept. 2022 08h00 HE
|
Ascendis Pharma
- Durability of response to TransCon PTH therapy through Week 110 demonstrated by continued normalization of serum calcium and 93% achieving independence from conventional therapy - Participants...